Biogen (NASDAQ:BIIB) Stock Price Target Raised at HC Wainwright

Posted by George Bondi on Nov 2nd, 2026

Biogen (NASDAQ:BIIB – Get Free Report) had its price target increased by equities research analysts at HC Wainwright from $251.00 to $270.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright‘s price target suggests a potential upside of 6.46% from the stock’s previous close.

BIIB has been the topic of a number of other research reports. Argus upgraded Biogen from a “hold” rating to a “buy” rating and set a $280.00 price objective on the stock in a research note on Thursday. Stifel Nicolaus set a $242.00 target price on Biogen in a research note on Thursday, September 10th. Truist Financial restated a “buy” rating and issued a $260.00 price target (up from $235.00) on shares of Biogen in a report on Thursday. Wolfe Research upgraded shares of Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective on the stock in a research note on Thursday, August 13th. Finally, Canaccord Genuity Group boosted their target price on shares of Biogen from $248.00 to $272.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.66.

Check Out Our Latest Stock Report on BIIB

Biogen Price Performance

BIIB stock opened at $253.62 on Monday. The stock has a market capitalization of $37.49 billion, a price-to-earnings ratio of 108.38, a price-to-earnings-growth ratio of 2.88 and a beta of 0.10. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39. Biogen has a 52-week low of $146.52 and a 52-week high of $258.78. The stock’s fifty day simple moving average is $227.08 and its 200-day simple moving average is $201.04.

Biogen (NASDAQ:BIIB – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. Biogen’s revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $4.81 earnings per share. Equities research analysts expect that Biogen will post 12.44 EPS for the current year.

Hedge Funds Weigh In On Biogen

Hedge funds have recently added to or reduced their stakes in the business. Align Financial LLC boosted its holdings in shares of Biogen by 339.3% in the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 95 shares during the period. Bell Investment Advisors Inc acquired a new stake in Biogen during the second quarter worth about $27,000. Provenance Wealth Advisors LLC bought a new position in Biogen in the third quarter worth about $29,000. Canton Hathaway LLC acquired a new position in Biogen in the third quarter valued at approximately $31,000. Finally, Ashurst Perkins Coie Trust Co boosted its stake in Biogen by 92.2% in the third quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 83 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Biogen

(Get Free Report)

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.